Telehealth Platform Differentiation: Adding Contactless Vital Signs

Telehealth platforms are facing a convergence problem. The core feature set, video calling, scheduling, messaging, and basic EHR integration, has been commoditized. Every platform on the market delivers some version of these capabilities, and the differences between them are shrinking. Enterprise buyers have noticed. RFP evaluations increasingly come down to price and implementation timeline rather than product capability, because the products all look fundamentally the same.

Contactless vital signs capture represents the most accessible and impactful differentiator available to telehealth platforms today. It moves the platform from a communication tool to a clinical measurement platform, changes the competitive conversation with enterprise buyers, and creates pricing power that video-only platforms cannot replicate.

This article lays out the go-to-market strategy for telehealth companies ready to make that move.

Positioning Vitals as a Competitive Moat

Differentiation only matters if it is defensible. Adding a feature that any competitor can replicate in a quarter does not change your market position. Contactless vitals capture through rPPG technology is defensible for three reasons.

Technical integration depth. Once vitals data flows into your platform, it touches clinical workflows, provider dashboards, EHR integrations, and reporting systems. Competitors cannot replicate just the measurement capability; they must replicate the entire integration, which takes months even with an existing SDK.

Longitudinal data advantage. Every visit that captures vitals adds to a patient's longitudinal physiological record within your platform. After six months of vitals-enabled visits, your platform holds trending data that a competitor's platform does not have. Health systems are reluctant to lose this historical data, which increases switching costs.

Provider workflow habit formation. When providers begin incorporating vitals data into their telehealth clinical workflow, reviewing heart rate before adjusting a beta-blocker dose, checking SpO2 as part of respiratory assessment, monitoring stress index trends for behavioral health patients, the platform becomes embedded in their clinical practice. Switching platforms means breaking clinical habits, which providers resist.

The first telehealth platform in a competitive evaluation that demonstrates live vitals capture during a demo changes the conversation. The evaluation shifts from "which platform offers the best video experience" to "which platform delivers clinical data." This is a fundamentally different buying criterion, and one where the platform with vitals has an asymmetric advantage.

Sales Enablement: Pitching Vitals to Health System Buyers

Your sales team needs to understand how vitals capability changes the conversation with each stakeholder in the health system buying process. The pitch is different for every persona at the table.

For the Chief Medical Officer

The CMO cares about care quality, patient safety, and clinical acceptability. The pitch: vitals capture during telehealth visits closes the clinical data gap that has made telehealth a second-class modality for complex patients. Providers gain objective measurements during virtual encounters, enabling better triage decisions, more confident medication management, and earlier detection of clinical deterioration. This is the capability that makes telehealth clinically equivalent to in-person care for a broader range of encounter types.

Proof points to prepare: clinical accuracy data for rPPG measurements, published validation studies against reference devices, and case examples of clinical decisions improved by telehealth vitals data.

For the VP of Digital Health

The digital health leader cares about program metrics, adoption rates, and demonstrating ROI to the C-suite. The pitch: vitals capability increases the clinical use cases that telehealth can support, expanding the addressable visit volume per provider. Departments that previously rejected telehealth as insufficient for their clinical workflows (cardiology, pulmonology, endocrinology) become potential adopters. Higher visit volume across more departments drives better utilization of the platform investment.

Proof points to prepare: data on telehealth visit volume increases after vitals capability launch, department expansion case studies, and provider satisfaction improvements.

For the CIO

The CIO cares about integration, security, data governance, and total cost of ownership. The pitch: rPPG vitals capture runs on-device in the patient's browser, meaning no facial video is transmitted to or processed by your servers. The vitals data payload is structured JSON that integrates with existing EHR systems via standard FHIR R4 Observation resources. The SDK adds minimal technical complexity to the existing platform deployment, and the data governance model is simpler than cloud-based alternatives because raw biometric data never leaves the patient's device.

Proof points to prepare: architecture diagrams showing on-device processing, FHIR resource mapping documentation, security and privacy compliance posture, and browser compatibility matrix.

For the CFO

The CFO cares about contract value, reimbursement impact, and competitive cost positioning. The pitch: vitals-enabled telehealth visits support higher reimbursement codes and better documentation for quality-based payment programs. The platform's vitals capability supports RPM billing codes (99453, 99454, 99457, 99458), creating a new revenue stream for the health system without requiring the purchase and distribution of consumer monitoring devices. From a cost perspective, fewer patients need to be routed to in-person visits solely for vitals capture, reducing facility utilization for low-acuity encounters.

Proof points to prepare: reimbursement analysis for vitals-enabled virtual visits versus video-only visits, RPM revenue projections, and cost avoidance estimates for reduced in-person visit routing.

For Procurement

Procurement cares about contract terms, vendor risk, and competitive alternatives. The pitch is less about vitals technology and more about competitive positioning. Emphasize that contactless vitals is an emerging capability that few platforms currently offer, creating a procurement advantage in securing a differentiated platform before competitors match the capability. Frame the vitals feature as a platform upgrade that enhances the value of the existing contract rather than a net-new procurement.

Pricing Strategies

How you price vitals capability determines whether it drives revenue growth or merely adds cost. Three models work in practice, and the right choice depends on your platform's existing pricing structure and target market segment.

Per-Visit Premium

Charge an additional fee for each visit where vitals are captured. This model works well for platforms that already price on a per-visit basis and for health systems that want to trial vitals capability without a large upfront commitment.

Typical pricing: an incremental charge per vitals-enabled visit on top of the standard per-visit rate. The premium is justified by the enhanced clinical data delivered during the encounter.

Advantages: low barrier to adoption, revenue scales directly with utilization, and the health system only pays for value delivered. Disadvantages: revenue is variable and depends on provider adoption of the vitals workflow.

Per-Provider License Tier

Create a premium license tier that includes vitals capability along with other advanced features (analytics, advanced reporting, clinical decision support). Providers on the premium tier have vitals enabled in all their visits.

Typical pricing: a monthly per-provider premium over the standard tier, representing a 20 to 35 percent uplift over the base license.

Advantages: predictable recurring revenue, simpler billing, and the tier structure encourages upselling. Disadvantages: health systems may resist paying the premium for all providers when only some clinical workflows benefit from vitals.

Enterprise License

For large health system deals, bundle vitals capability into an enterprise license that covers unlimited providers and visits. Price the enterprise license at a level that reflects the full clinical and operational value of vitals across the organization.

Typical structure: annual enterprise contract with a significant premium over the per-provider pricing, but with economies of scale that make it more cost-effective at volume.

Advantages: maximizes contract value, simplifies procurement, and drives organization-wide adoption. Disadvantages: requires executive-level buy-in and a longer sales cycle.

The most effective approach for most platforms is to launch with per-visit pricing to drive initial adoption and generate case study data, then migrate successful accounts to per-provider or enterprise licensing as the value is proven.

Customer Success Framework

Launching vitals capability is not just a product release. It requires a customer success motion that drives provider adoption and demonstrates clinical value.

Provider Onboarding

Providers need to understand what vitals data is available, how to interpret confidence scores, and how to incorporate vitals into their clinical workflow. This is not a lengthy training process. A ten-minute video and a one-page quick reference guide cover the essentials. But the onboarding must happen, or providers will ignore the capability.

Structure onboarding around clinical use cases rather than technology features. Show providers how to use vitals data during a medication management visit, a triage encounter, and a chronic disease follow-up. Make it clinically relevant, not technically impressive.

Adoption Tracking

Measure vitals utilization at the provider, department, and organizational level. Track the percentage of eligible visits where vitals are captured, the average signal quality score, and provider feedback. Identify providers who are not using the capability and understand why. Common barriers include workflow friction (the capture step is too intrusive), lack of awareness (the provider did not know the feature was available), and clinical skepticism (the provider does not trust camera-based measurements).

Address each barrier with targeted interventions: workflow optimization for friction, communication campaigns for awareness, and clinical evidence sharing for skepticism.

Value Demonstration

Your customer success team should produce quarterly value reports for each health system customer, showing the volume of vitals captured, clinical workflow improvements (reduced in-person visit routing, expanded specialty adoption), and outcome metrics where available. These reports justify contract renewal and expansion.

The value report is also your most powerful sales tool for new prospects. Anonymized aggregate data from existing customers provides the evidence that new buyers need to justify the investment.

Partner Ecosystem Opportunities

Vitals capability creates partnership opportunities that extend your platform's value beyond the core telehealth visit.

EHR vendors. Deep integration with EHR systems for vitals data flow creates co-selling opportunities. EHR vendors want their customers to have richer clinical data in the record, and your platform delivers it. Joint marketing, co-development of integration workflows, and referral agreements with EHR vendors amplify your go-to-market reach.

RPM service providers. Companies that manage remote patient monitoring programs need data sources. rPPG vitals capture from both telehealth visits and standalone patient measurements provides a no-hardware data stream that complements their existing device-based programs. Partnership models include data integration agreements, white-label arrangements, and joint offerings.

Clinical analytics companies. Population health platforms and clinical analytics vendors benefit from the physiological data your platform generates. Anonymized, aggregated vitals data from telehealth encounters has research and analytics value. Partnerships with analytics companies can create additional revenue streams and enhance the clinical evidence base for rPPG technology.

Health plan and payer partners. Health plans are increasingly interested in virtual care platforms that deliver measurable clinical value. Vitals data from telehealth visits supports value-based care programs, risk stratification, and care gap identification. Payer partnerships can include preferred vendor status, incentive alignments, and co-funded implementation programs.

Market Timing: Why Now

Three converging trends make this the optimal moment for telehealth platforms to add contactless vitals.

Post-Pandemic Telehealth Maturity

The pandemic-era surge in telehealth adoption has settled into a mature market. Health systems are no longer scrambling to deploy any virtual care solution; they are evaluating platforms based on clinical capability and long-term value. This maturation favors platforms that offer more than video connectivity. Buyers are ready to invest in clinical differentiation because they have stabilized their core telehealth operations and are looking for the next level of capability.

CMS Virtual Care Expansion

CMS continues to expand and codify coverage for virtual care services. The extension of telehealth flexibilities, the expansion of RPM billing codes, and the increasing emphasis on quality documentation for virtual encounters all create financial incentives for health systems to adopt telehealth platforms with clinical measurement capabilities. The regulatory trajectory is clear: virtual care is expected to deliver clinical data, and platforms that enable this will be favored.

rPPG Technology Readiness

Five years ago, camera-based vitals measurement was a research demonstration. Today, rPPG technology has been validated in clinical studies, optimized for real-world conditions (diverse skin tones, variable lighting, consumer-grade cameras), and packaged in production-ready SDKs that integrate in weeks rather than years. Circadify's on-device processing approach solves the privacy and latency challenges that previously limited cloud-based rPPG implementations.

The convergence of a mature market demanding clinical differentiation, regulatory incentives rewarding clinical data capture, and a ready technology solution creates a strategic window. Telehealth platforms that move through this window now will establish market position, accumulate longitudinal data advantages, and embed themselves in clinical workflows before competitors can respond.

The platforms that wait will find themselves in a market where vitals capability has become a baseline expectation rather than a differentiator, competing to catch up rather than leading the category.